Fremanezumab is safe, effective, and tolerable for children and adolescents with episodic migraine, reducing monthly migraine ...

Results from the Phase III SPACE trial show that Ajovy significantly reduced monthly migraines in pediatric patients between ...

The FDA has accepted for review the sBLA for fremanezumab-vfrm for the prevention of episodic migraine in pediatric patients aged 6 to-17 years weighing at least 45 kg.

Is your child complaining of frequent headaches? Are they missing school days or activities they love? Headaches in children are a common issue, but understanding the causes and how to manage them can ...

Lurie Children’s Hospital ... She noted that pediatric migraine treatment studies are always valuable, especially given the limited evidence-based pharmacological options available for young ...

This is why migraines in children need to be thoroughly assessed and continually monitored so that the root cause of the ...

If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist ...

In children and teenagers, treatment with zonisamide was associated with a significant reduction in the number of monthly ...

it was not possible to correlate headache outcome with specific treatment modality. Nevertheless, these drawings accurately predicted the clinical course in the vast majority of children.

Existing treatments for endometriosis have changed little in the past 30 years and are often ineffective or have undesired ...

Headaches can be complicated. Different kinds can have their own set of symptoms, causes, and need different treatments. Where your head hurts isn't a foolproof way to diagnose, but the location ...

“Migraine is common among children and adolescents, often disrupting their education, social lives and overall well-being, yet treatment options remain limited,” said Eric Hughes, MD ...